Edition:
India

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

11.52USD
17 Nov 2017
Change (% chg)

$0.34 (+3.04%)
Prev Close
$11.18
Open
$11.35
Day's High
$11.90
Day's Low
$11.35
Volume
1,303,094
Avg. Vol
932,041
52-wk High
$13.38
52-wk Low
$6.74

Chart for

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $2,368.37
Shares Outstanding(Mil.): 192.24
Dividend: --
Yield (%): --

Financials

BRIEF-Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting

* Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting

13 Nov 2017

BRIEF-ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018

31 Oct 2017

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

14 Sep 2017

BRIEF-Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

* Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma

12 Sep 2017

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-Array Biopharma reports Q4 loss per share $0.17

* Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017

09 Aug 2017

BRIEF-Amgen and Array BioPharma announce preclinical license and collaboration agreement

* Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

18 Jul 2017

BRIEF-Array Biopharma submits new drug applications to FDA

* Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma

05 Jul 2017

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

31 May 2017

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

31 May 2017

Earnings vs. Estimates